GAITHERSBURG, Md., Oct. 29 /PRNewswire/ -- Sequoia Pharmaceuticals, Inc., which discovers and develops novel antiviral therapeutics as well as pharmacokinetic enhancers, announced today the appointment of Steven D. Skolsky as its President and Chief Executive Officer. He will also serve as a member of the Board of Directors.
"Sequoia is pleased to have recruited such an outstanding, talented leader as Steven Skolsky," said Chris Mirabelli, Chairman of the Board of Sequoia Pharmaceuticals. "Steve has an impressive record of success within the pharmaceutical industry. The combination of his leadership and management experience, as well as his business acumen, makes Steve uniquely qualified to lead us through the exciting times ahead."
"Sequoia possesses an extraordinary scientific pedigree, and a very attractive research portfolio. I am honored to have the opportunity to lead Sequoia, and to build on its outstanding technological progress as we move towards commercialization", said Mr. Skolsky.
Mr. Skolsky brings over twenty-five years of U.S. and international experience in the pharmaceutical and biotechnology arena. He most recently served as chief executive officer of Trimeris, a biotechnology company specializing in HIV therapeutics. Previously Mr. Skolsky had a distinguished career at GlaxoSmithKline where he served as GSK's Senior Vice President of Global Commercial Strategy responsible for world-wide clinical development and product strategy. He also served as managing director of GSK's operations in Australia and New Zealand and previously was Vice President of Sales and Marketing of the HIV/Oncology Division at Glaxo Wellcome. He is a graduate of the University of North Carolina at Chapel Hill.
About Sequoia Pharmaceuticals, Inc.
Sequoia Pharmaceuticals discovers and develops revolutionary new treatments, primarily for viral diseases including HIV/AIDS and HCV-induced hepatitis. In addition, Sequoia has an active R&D program in pharmacokinetic enhancers.
|SOURCE Sequoia Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved